These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 16564154)

  • 1. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
    Mihai R; Stevens J; McKinney C; Ibrahim NB
    Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients.
    Gao D; Du J; Cong L; Liu Q
    Jpn J Clin Oncol; 2009 Feb; 39(2):97-104. PubMed ID: 19052036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer.
    Parker BS; Ciocca DR; Bidwell BN; Gago FE; Fanelli MA; George J; Slavin JL; Möller A; Steel R; Pouliot N; Eckhardt B; Henderson MA; Anderson RL
    J Pathol; 2008 Feb; 214(3):337-46. PubMed ID: 17985332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
    Henderson MA; Danks JA; Slavin JL; Byrnes GB; Choong PF; Spillane JB; Hopper JL; Martin TJ
    Cancer Res; 2006 Feb; 66(4):2250-6. PubMed ID: 16489028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of osteopontin in patients with triple-negative breast cancer.
    Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
    Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases.
    Bouizar Z; Spyratos F; Deytieux S; de Vernejoul MC; Jullienne A
    Cancer Res; 1993 Nov; 53(21):5076-8. PubMed ID: 8221637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
    Wang YJ; Wang N; Wang B; Qin WX; Xue CY
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary metastases of breast cancer. When is resection indicated?
    Welter S; Jacobs J; Krbek T; Tötsch M; Stamatis G
    Eur J Cardiothorac Surg; 2008 Dec; 34(6):1228-34. PubMed ID: 18824371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
    Kolár Z; Murray PG; Zapletalová J
    Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.